Emerging antibody-based therapies for the treatment of acute myeloid leukemia
METADATA ONLY
Loading...
Author / Producer
Date
2022-07
Publication Type
Review Article
ETH Bibliography
yes
Citations
Altmetric
METADATA ONLY
Data
Rights / License
Abstract
The development of antibody-based therapeutics for patients with acute myeloid leukemia (AML) has long been hampered due to the shared expression of antigens on leukemic blasts and hematopoietic stem and progenitor cells (HSPC). Nevertheless, the first antibody-drug conjugate has been approved for the treatment of AML in the recent years. In addition, multiple antibody-based therapeutics including antibody-drug conjugates, bispecific antibodies and immunocytokines are currently being developed in clinical trials with some of them demonstrating encouraging results alone and/or in combination with current standard therapies. In this review we discuss current concepts of antibody-based therapies and results from emerging antibody-based therapeutics for the treatment of AML.
Permanent link
Publication status
published
External links
Editor
Book title
Journal / series
Volume
108
Pages / Article No.
102409
Publisher
Elsevier
Event
Edition / version
Methods
Software
Geographic location
Date collected
Date created
Subject
Antibody; Antibody-drug conjugates; Immunocytokines; Bispecific antibodies; Acute Myeloid Leukemia; AML